

Contents

Introduction XIII

Glossary and Abbreviations XV

Part I Introduction 1

1	The Drug Discovery Process	3
1.1	Pharmacokinetics–Structure Relationship	5
1.2	The Future of Small-Molecule Drugs	9
	References	11
2	Lead Optimization	13
2.1	What Limits/Reduces Oral Bioavailability?	14
2.2	What Limits/Reduces Plasma Half-Life?	15
2.3	How to Improve bbb-Penetration?	16
2.4	How to Avoid CYP Inhibition/Induction?	16
2.5	How to Avoid Interaction with the Human Ether-à-go-go-Related Gene (hERG)?	17
2.6	How to Prevent Toxicity?	17
2.7	Examples of PK-Optimization in Animals	20
2.7.1	Dihydroorotate Dehydrogenase Inhibitors	20
2.7.2	Matrix Metalloproteinase Inhibitors	21
2.7.3	Antibacterial Aminobenzenesulfonamides	21
2.7.4	Tyrosine Kinase Inhibitors	22
2.7.5	5-HT _{1A} Agonists	23
2.7.6	Dipeptidyl Peptidase IV Inhibitors; Structural Variations of Sitagliptin	23
2.7.7	P-Selectin Inhibitors	24
2.7.8	β ₃ -Adrenergic Agonists	24
2.7.9	Vanilloid-1 Antagonists	25
2.7.10	HIV Protease Inhibitors	25
2.7.11	Matrix Metalloproteinase Inhibitors (Tested in Rats)	26
2.7.12	HIV Integrase Inhibitors	26
2.7.13	Dopamine D ₃ Antagonists	27
2.7.14	Inhibitors of Soluble Epoxide Hydrolase (Tested in Mice, po)	28

2.7.15	Melanin-Concentrating Hormone Receptor-1 Antagonists	29
	References	29

Part II The Pharmacokinetic Properties of Compound Classes 33

3	Alkanes	35
3.1	Metabolism	36
	References	39
4	Alkenes and Alkynes	40
4.1	Metabolism	40
	References	44
5	Arenes	45
5.1	Metabolism	45
6	Halides	49
6.1	Fluorine	49
6.2	Chlorine	51
6.3	Bromine	53
6.4	Iodine	53
6.5	Alkylating Agents	54
	Reference	55
7	Azides	58
8	Nitro Compounds	59
8.1	Metabolism	60
9	Azo Compounds	62
10	Triazenes	64
11	Nitrates and Nitrites	66
	Further Reading	67
12	N-Nitroso Compounds	68
13	N-Oxides	70
14	Alcohols	71
14.1	Metabolism	72

15	Phenols	82
	References	84
16	Ethers	91
16.1	Metabolism	92
	Reference	93
17	Epoxides	96
18	Peroxides	97
19	Thiols	98
20	Thioethers	100
20.1	Metabolism	101
	Reference	103
21	Sulfoxides	104
22	Sulfones	106
23	Aliphatic Amines	107
23.1	Basicity	110
23.2	Metabolism	110
23.3	Rates of N-Dealkylation	112
	Reference	114
24	Quaternary Ammonium Salts	118
	Reference	119
25	Amidines	120
	Reference	121
26	Guanidines, Acylguanidines, and Biguanides	122
26.1	Acylguanidines	123
26.2	Biguanides	123
	Reference	124
27	Anilines	133
27.1	Metabolism	135
28	Hydrazines, Acylhydrazines, and Hydrazones	137

29	Aldehydes	138
30	Ketones	139
31	Carboxylic Acids	144
31.1	Metabolism	145
31.2	Bioisosteres of Carboxylic Acids	146
31.3	Amino Carboxylic Acids, <i>N</i> -Acyl Amino Acids, and Related Compounds	147
	References	148
32	Carboxylic Esters	164
	Reference	165
33	Amides	166
34	Lactams and Imides	172
34.1	Pyrazolone Antipyretics	172
34.2	Five-Membered Lactams as Nootropics	173
	References	174
35	Nitriles	184
	References	185
36	Carbonates	186
37	Carbamates	187
37.1	Carbamates as Hypnotics	188
	References	189
38	Ureas	192
	Reference	193
39	Thiocarbonyl Compounds	201
40	Sulfonic Acids	203
41	Sulfonic Esters	206
42	Sulfates and Sulfamic Acids	207
43	Phosphonic Acids	209

- 44 Phosphoric Acid Derivatives 213**
- 45 N-(Aminoalkyl)benzamides, -Benzoates, and Related Compounds 215**
Reference 216
- 46 Arylalkylamines 225**
46.1 Antihistaminics: History 225
Reference 226
- 47 Phenethylamines (2-Phenylethylamines) 267**
47.1 Biological Activity of Phenethylamines 267
47.2 Metabolism 268
47.3 Tetrahydroisochinolines and Related Compounds 269
Further Reading 270
- 48 Aminoalkylindoles and Indole Alkaloids 291**
Reference 291
- 49 Phenothiazines 301**
49.1 Metabolism 302
References 302
- 50 Dibenzazepines and Related Tricyclic Compounds 310**
- 51 3-Aryloxy-2-Hydroxypropylamines
(β -Adrenergic Antagonists; " β -Blockers") 320**
51.1 Metabolism 320
- 52 Opiates 329**
Reference 329
- 53 N-(Carboxyalkyl)- α -Amino Acid Amides (Prils) 335**
Reference 336
- 54 Anilides and Amides of Glycine 341**
- 55 Peptides, Peptidomimetics, and Related Oligoamides 347**
55.1 Peptidomimetics 348
55.2 Thrombin Inhibitors and Related Compounds 349
References 350

- 56** **Oligoarylamines, Oligoarylamides, Oligoarylcarbamates, and Oligoarylureas** 365
References 365
- 57** **Imidazoles** 377
References 378
- 58** **Triazoles** 387
- 59** **Pyridines, Pyrimidines, and Related Compounds** 393
59.1 Proton Pump Inhibitors 396
References 397
- 60** **Quinolines** 412
60.1 Tecans 415
60.2 Quinazolines 415
References 416
- 61** **Nucleoside Analogs** 428
Reference 428
- 62** **Dihydropyridines** 446
- 63** **Arenesulfonamides** 450
63.1 Antibacterials 450
63.2 Diuretics 450
Reference 451
- 64** **Sulfonylureas** 462
- 65** **Benzodiazepines** 466
Reference 467
- 66** **Steroids** 477
References 478
- 67** **Anthracyclines** 492
- 68** **Arylacetic, Benzoic, and Related Carboxylic Acids (NSAIDS)** 497
68.1 Salicylates 497
References 498

69	Quinolonecarboxylic Acids (Gyrase Inhibitors)	514
70	β-Lactams	522
70.1	Cephalosporins	523
	Reference	523
71	Prostaglandin Analogs	538
72	Sartans	543
	Reference	544
73	Statins	548
74	Folic Acid Analogs (Antifolates)	551
75	Taxanes	554
	Reference	554
76	Macrocyclic Compounds	557
	Reference	557
	Index	567

